Considerations for the definition of remission criteria in psoriatic arthritis by Mease, P, Coates, L

Measuring outcomes in psoriatic arthritis by Ogdie, A, Coates, LC, Mease, P

GRAPPA 2016 Project Report by Helliwell, P, Fitzgerald, O, Coates, L, Callis Duffin, K, Mease, P

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certoli... by Hazes, J, Taylor, P, Strand, V, Purcaru, O, Coteur, G, Mease, P

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of... by Choy, E, Gladman, D, Mease, P, Wordsworth, P, Ritchlin, C, Wang, H, Sasso, E

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psori... by Coates, L, Kishimoto, M, Gottlieb, A, Shuler, C, Lin, C, Lee, C, Mease, P

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) by Mease, P, Gladman, D, Samad, A, Coates, L, Liu, L, Aras, G, Collier, D, Chung, J

Classification and outcome measures for psoriatic arthritis by Leung, Y, Ogdie, A, Orbai, A, Tillett, W, Coates, L, Strand, V, Mease, P, Gladman, D

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies by Tillett, W, Orbai, A, Ogdie, A, Leung, Y, Strand, V, Gladman, D, Mease, P, Coates, L

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis by Coates, L, Gossec, L, Ramiro, S, Mease, P, Van Der Heijde, D, Smolen, J, Ritchlin, C, Kavanaugh, A

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐co... by Coates, L, Mease, P, Gossec, L, Kirkham, B, Sherif, B, Gaillez, C, Mpofu, S, Jugl, S, Karyekar, C, Gandhi, K

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... by Coates, LC, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Measurement properties of the minimal disease activity criteria for psoriatic arthritis by Coates, L, Strand, V, Wilson, H, Revicki, D, Stolshek, B, Samad, A, Chung, J, Gladman, D, Mease, P

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... by Coates, L, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

International treatment recommendations update: A report from the GRAPPA 2016 annual meeting by Coates, L, Chandran, V, Ogdie, A, O'Sullivan, D, Brooke, M, Steinkoenig, I, Mease, P, Ritchlin, C, Kavanaugh, A

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial by Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial by van der Heijde, D, Luo, M, Matsumoto, A, Mease, P, Torre-Alonso, J, Wordsworth, B, Wong, R, Davis, J

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial by Baraliakos, X, Pournara, E, Gossec, L, Mease, P, White, R, O’Brien, E, Schulz, B, Marzo Ortega, H, Coates, LC

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation by Taylor, P, Mease, P, Bushmakin, A, Cappelleri, J, Fleischmann, R, Fallon, L, Woolcott, J, Ogdie, A, Azevedo, V, De Vlam, K

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial. by Van der Heijde, D, Luo, M, Matsumoto, A, Mease, P, Torre-Alonso, J, Wordsworth, P, Wong, R, Davis, J, Grp, A